Inhibitor Report for: Piperidinone-constrained-phenethylamine-31 General
Type Benzodioxo , Trifluoro , Piperidine Chemical_Nomenclature (4R,5R)-5-amino-1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(2,4,5-trifluorophenyl)piperidin-2-one Canonical SMILES C1C(C(CN(C1=O)CCC2=CC3=C(C=C2)OCO3)N)C4=CC(=C(C=C4F)F)F InChI InChI=1S/C20H19F3N2O3/c21-14-8-16(23)15(22)6-12(14)13-7-20(26)25(9-17(13)24)4-3-11-1-2-18-19(5-11)28-10-27-18/h1-2,5-6,8,13,17H,3-4,7,9-10,24H2/t13-,17+/m1/s1 InChIKey DIRIFWIKLRTNMB-DYVFJYSZSA-N Other name(s) GGO ; (4R,5R)-5-amino-1-[2-(2H-1,3-benzodioxol-5-yl)ethyl]-4-(2,4,5-trifluorophenyl)piperidin-2-one ; Piperidinone-Constrained Phenethylamine 31 ; CHEMBL225210 ; BDBM15510
________________________________________________________________________________________________
Target
Families | Piperidinone-constrained-phenethylamine-31 ligand of proteins in family: DPP4N_Peptidase_S9 Stucture | 1 structure : 2OQI : Human Dipeptidyl Peptidase IV (DPP4) with Piperidinone-constrained phenethylamine Protein | human-DPP4
References:
Title: Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitorsPei Z , Li X , von Geldern TW , Longenecker K , Pireh D , Stewart KD , Backes BJ , Lai C , Lubben TH and Trevillyan JM <4 more author(s)> Pei Z , Li X , von Geldern TW , Longenecker K , Pireh D , Stewart KD , Backes BJ , Lai C , Lubben TH , Ballaron SJ , Beno DW , Kempf-Grote AJ , Sham HL , Trevillyan JM (- 4) Ref: Journal of Medicinal Chemistry, 50 :1983, 2007 : PubMed Abstract ESTHER: Pei_2007_J.Med.Chem_50_1983 PubMedSearch: Pei 2007 J.Med.Chem 50 1983 PubMedID: 17367123 Gene_locus related to this paper: human-DPP4 Inhibitor(s) related to this paper: Piperidinone-constrained-phenethylamine-31 ,
Piperidine-constrained-phenethylamine-42 Abstract
Dipeptidyl peptidase IV (DPP4) inhibitors are emerging as a new class of therapeutic agents for the treatment of type 2 diabetes. They exert their beneficial effects by increasing the levels of active glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, which are two important incretins for glucose homeostasis. Starting from a high-throughput screening hit, we were able to identify a series of piperidinone- and piperidine-constrained phenethylamines as novel DPP4 inhibitors. Optimized compounds are potent, selective, and have good pharmacokinetic profiles.
